Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current. Investigators randomized 81 adults with chronic rhinosinusitis with nasal ...
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...
Thank you for standing by, and welcome to the Upstream Bio Phase II VIBRANT Top-line Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session - ...
Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...
BP (LSE:BP) is increasing its focus on U.S. shale output as a core part of its renewed emphasis on upstream oil and gas. The company is prioritising new upstream projects in the U.S. as it rebalances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results